BTT-1023 in Rheumatoid Arthritis

Summary

Patients with adult-onset rheumatoid arthritis will be enrolled. They will be dosed with repeated intravenous doses of BTT-1023 or placebo. During the trial, the safety of the treatments and the pharmacokinetics of BTT-1023 will be assessed. The patient allocation to treatment groups will occur at random, and the actual treatment will not be revealed to the investigator or to the patient during the trial.

Timeline

Start

2009-02

Primary completion

2009-11

Completion

2009-11

Drugs

Indications